John Yates
GlaxoSmithKline (United Kingdom)(GB)Molecular Discovery (United Kingdom)(GB)
Publications by Year
Research Areas
Cancer, Lipids, and Metabolism, Lipoproteins and Cardiovascular Health, Peroxisome Proliferator-Activated Receptors, Cholesterol and Lipid Metabolism, Wnt/β-catenin signaling in development and cancer
Most-Cited Works
- → Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription(2000)888 cited
- → Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma(2014)472 cited
- → The role of ATP citrate-lyase in the metabolic regulation of plasma lipids(1998)137 cited
- → Synthetic LXR agonists increase LDL in CETP species(2005)118 cited
- → Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3β on a muscle-specific promoter(2004)106 cited
- → Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium‐derived factor: Two novel biomarkers of Alzheimer's disease in human plasma(2008)56 cited
- → ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme(1996)33 cited
- Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.(1998)
- → ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. 2. Synthesis and Evaluation of (3R*,5S*)-ω-Substituted-3-carboxy-3,5-dihydroxyalkanoic Acids and Their γ-Lactone Prodrugs as Inhibitors of the Enzyme in Vitro and in Vivo(1998)30 cited
- → SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis(1997)25 cited